Shiseido Co. agreed will sell its shampoo and affordable skin-care business to CVC Capital Partners for $1.5 billion, as it shifts more focus to making and selling high-end skin products.
Under the deal, Shiseido will transfer its personal-care business to a holding company where CVC is an investor. Shiseido will then acquire a 35 percent stake in the holding company that will operate the business. CVC will oversee the new company, which may go public in the future.
The transfer price of the business and assets are valued at 160 billion yen with a transfer date set for July 2021.
The Japanese beauty giant has been revamping its portfolio with the pandemic changing cosmetic and personal care routines.
Among the businesses to be divested are its drugstore brands, including Tsubaki hair-care products and Senka face wash.
Shiseido has been contemplating about the future of its personal care business as it had not been able to give it the marketing and research and development resources it needed to grow.
The lifestyle and personal care business represented about 10 percent of Shiseido’s revenue in 2019, with annual sales of about 100 billion yen.
According to Shiseido CEO Masahiko Uotani, CVC and other groups have approached them about acquiring the segment. But he thought at that time that it was too premature to even when they began feeling the impact of the coronavirus pandemic.
Uotani noted that the personal care business model is very different from its focus as a beauty company.


Trump Defends Economic Record in North Carolina as Midterm Election Pressure Mounts
JPMorgan’s Top Large-Cap Pharma Stocks to Watch in 2026
Maersk Vessel Successfully Transits Red Sea After Nearly Two Years Amid Ongoing Security Concerns
Why U.S. Coffee Prices Are Staying High Despite Trump’s Tariff Rollbacks
Global Demand for Yuan Loans and Bonds Surges as China Pushes Currency Internationalization
Platinum Price Surges Past $2,000 as Demand and Supply Dynamics Tighten
Uber and Baidu Partner to Test Robotaxis in the UK, Marking a New Milestone for Autonomous Ride-Hailing
Asian Stocks Rise as Wall Street Tech Rally Lifts Markets, Yen Slumps Despite BOJ Rate Hike
AstraZeneca’s LATIFY Phase III Trial of Ceralasertib Misses Primary Endpoint in Lung Cancer Study
Warner Bros Discovery Weighs Amended Paramount Skydance Bid as Netflix Takeover Battle Intensifies
FDA Fast-Tracks Approval of Altria’s on! PLUS Nicotine Pouches Under New Pilot Program
Elon Musk Wins Reinstatement of Historic Tesla Pay Package After Delaware Supreme Court Ruling
China Keeps Benchmark Lending Rates Steady as Economic Outlook Remains Cautious
Volaris and Viva Agree to Merge, Creating Mexico’s Largest Low-Cost Airline Group
Wall Street Ends Higher as S&P 500, Nasdaq Extend Gains Ahead of Holiday Week
Trump Signals Push for Lower Health Insurance Prices as ACA Premium Concerns Grow 



